President Trump recently criticized the FDA approval process as "slow and burdensome" but failed to offer up specific plans for reform. If FDA standards were to be altered, the market could see an avalanche of new drugs and treatments. TheStreet's Adam Feuerstein compiled the "Gnarly Nine" companies that could be interesting to watch as the FDA enters the Trump era. 

  1. Alkermes (ALKS)
  2. CytRX (CYTR)

  3. Dynavax Technologies (DVAX)

  4. Intra-Cellular Therapies (ITCI)

  5. Novan (NOVN)

  6. Portola Pharmaceuticals (PTLA)

  7. PTC Therapeutics (PTCT)

  8. Rigel Pharmaceuticals (RIGL)

  9. TG Therapeutics (TGTX)

READ THE FULL STORY HERE: These 'Gnarly 9' Biotechs Will Test the FDA's Mettle

This article was written by a staff member of TheStreet.

More from Video

Is the Cannabis Crazy Equivalent to the Dot Com Bubble? Watch!

Is the Cannabis Crazy Equivalent to the Dot Com Bubble? Watch!

Economist Perspective: Rising Wages

Economist Perspective: Rising Wages

Eventbrite Shares Surge in NYSE Debut

Eventbrite Shares Surge in NYSE Debut

60 Seconds: The Documents You Need in a Disaster

60 Seconds: The Documents You Need in a Disaster

Need Some Income for Your Portfolio? Consider Closed-End Funds

Need Some Income for Your Portfolio? Consider Closed-End Funds